Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
- 26 January 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2501486
Abstract
PURPOSE: Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer. PATIENTS AND METHODS: Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash–Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms. RESULTS: Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 ( P = .02), and 6.89 ( P < .001), respectively. Daily hot flash scores for placebo, 2.5 mg oxybutynin, and 5 mg oxybutynin reduced by an average of 4.85, 9.94 ( P = .07), and 13.95 ( P = .002) points, respectively. No treatment-related grade 3+ AEs occurred. HFRDIS total scores improved by 14.2 and 20.7 points in the 2.5 mg ( P = .042) and 5 mg ( P < .01) oxybutynin arms, respectively, compared with a 3.1-point improvement with placebo. CONCLUSION: Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.Keywords
This publication has 26 references indexed in Scilit:
- Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single institution experienceClinical and Translational Radiation Oncology, 2018
- Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturiaCancer, 2017
- Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor SymptomsJAMA Internal Medicine, 2014
- Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trialPsycho-Oncology, 2013
- Randomised, Multicentre, Placebo-controlled, Double-blind Crossover Study Investigating the Effect of Solifenacin and Oxybutynin in Elderly People with Mild Cognitive Impairment: The SENIOR StudyEuropean Urology, 2013
- Prostate cancer treatments and their side effects are associated with increased insomniaPsycho-Oncology, 2012
- Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United StatesUrologic Oncology: Seminars and Original Investigations, 2011
- Differential Effects of the Antimuscarinic Agents Darifenacin and Oxybutynin ER on Memory in Older SubjectsEuropean Urology, 2006
- The Hot Flash Related Daily Interference ScaleJournal of Pain and Symptom Management, 2001
- Dimensions of quality of life expressed by men treated for metastatic prostate cancerSocial Science & Medicine, 1997